Discover
VERV
Verve Therapeutics, Inc.
11.13
undefined x undefined
undefined x undefined
bid
ask
+
11.13
0.00%
07:00 PM
| Ytd | 97.34% | |
| 1y | 57.20% |
day range
52 week range
| Open | Prev Close | Low | High | Mkt Cap | N/A | ||||
| Vol | 0.00 | Avg Vol | 0.00 | EPS | N/A | P/E | N/A | Forward P/E | -2.04 |
| Beta | 1.76 | Short Ratio | 11.25 | Inst. Own | 97.87% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | N/A | 50-d Avg | N/A | 200-d Avg | N/A | 1yr Est | 26.20 |
| Income Statement | |||
| Total Revenue | 32.98M | ||
| Revenues (USD) | 32.98M | ||
| Gross Profit | 32.98M | ||
| Operating Expenses | 69.61M | ||
| Research and Development Expense | 54.46M | ||
| Selling, General and Administrative Expense | 15.15M | ||
| Operating Income | -36.64M | ||
| Income Tax Expense | 79.00K | ||
| Net Income | -31.03M | ||
| Net Income Common Stock | -31.03M | ||
| Net Income Common Stock (USD) | -31.03M | ||
| Consolidated Income | -31.03M | ||
| Earnings per Basic Share | -0.35 | ||
| Earnings per Basic Share (USD) | -0.35 | ||
| Earnings per Diluted Share | -0.35 | ||
| Earning Before Interest & Taxes (EBIT) | -30.95M | ||
| Earning Before Interest & Taxes (USD) | -30.95M | ||
| Weighted Average Shares | 88.80M | ||
| Weighted Average Shares Diluted | 88.80M | ||
| Balance Sheet | |||
| Cash and Equivalents | 101.33M | ||
| Cash and Equivalents (USD) | 101.33M | ||
| Investments | 400.52M | ||
| Investments Current | 400.52M | ||
| Trade and Non-Trade Receivables | 1.40M | ||
| Current Assets | 511.65M | ||
| Property, Plant & Equipment Net | 94.67M | ||
| Total Assets | 614.16M | ||
| Total Debt | 58.12M | ||
| Current Liabilities | 51.98M | ||
| Debt Non-Current | 58.12M | ||
| Total Liabilities | 140.65M | ||
| Accumulated Retained Earnings (Deficit) | -774.05M | ||
| Accumulated Other Comprehensive Income | 393.00K | ||
| Shareholders Equity | 473.51M | ||
| Shareholders Equity (USD) | 473.51M | ||
| Assets Non-Current | 102.51M | ||
| Total Debt (USD) | 58.12M | ||
| Deferred Revenue | 48.58M | ||
| Liabilities Non-Current | 88.67M | ||
| Trade and Non-Trade Payables | 5.35M | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 3.58M | ||
| Net Cash Flow from Financing | 7.00K | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | -76.01M | ||
| Capital Expenditure | -1.22M | ||
| Issuance (Purchase) of Equity Shares | 7.00K | ||
| Net Cash Flow from Investing | -48.17M | ||
| Net Cash Flow - Investment Acquisitions and Disposals | -46.94M | ||
| Net Cash Flow from Operations | -27.84M | ||
| Share Based Compensation | 11.17M | ||